MedTrace Logo

Impact of Amyloidosis on TAVI Patients

NCT03984877 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 320

Last updated 2019-06-14

No results posted yet for this study

Summary

To analyze the prevalence and impact on the prognosis of amyloidosis due to transthyretin in patients with severe aortic stenosis who undergo percutaneous aortic valve implantation.

Conditions

  • Valve Stenoses, Aortic
  • Amyloidosis Cardiac

Interventions

DIAGNOSTIC_TEST

Diagnosis of amyloidosis

Scintigraphy and protein electrophoresis

Sponsors & Collaborators

  • Javier López Pais

    lead OTHER

Principal Investigators

  • Jose Ramón Gonzalez Juantey, M.D. Ph.D. · Complexo Hospitalario Universitario de Santiago de Compostela

Eligibility

Min Age
60 Years
Max Age
110 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03984877 on ClinicalTrials.gov